CTLA-4 and PD-1/PD-L1 are primary targets for immune checkpoint inhibitors (ICIs), some of which are currently approved or in clinical trials for HCC (Zhang et al., 2017; Seidel et al., 2018). Here, CTLA4 is linked to hepatocellular carcinoma.